Identification and analysis of the risk of liver-related adverse drug reaction in pregnant women
10.3969/j.issn.1001-5256.2022.08.021
- VernacularTitle:妊娠女性药物相关肝损伤风险的识别及分析
- Author:
Guangdi MU
1
,
2
;
Jiayi LI
2
,
3
;
Yunjuan GAO
2
;
Xu ZHAO
2
;
Jiabo WANG
2
;
Zhaofang BAI
2
;
Xiaohe XIAO
2
;
Yuming GUO
2
Author Information
1. Graduate School, Guizhou University of Traditional Chinese Medicine, Guizhou 550025, China
2. Department of Liver Disease, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
3. College of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 102488, China
- Publication Type:Original Articles_Other Liver Diseases
- Keywords:
Pregnancy;
Chemical and Drug Induced Liver Injury;
Drug-Related Side Effects and Adverse Reactions
- From:
Journal of Clinical Hepatology
2022;38(8):1834-1838
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the potential medication risk by identifying and analyzing the features of liver-related adverse drug reaction (ADR) in pregnant women. Methods A retrospective study was performed for the reports on liver-related ADR in pregnant women from January 1, 2012 to December 31, 2016 in HILI Cloud (hilicloud.net). Main clinical features and medication rules were analyzed, and reporting odds ratio ( ROR ) was used to analyze the relative risk of related drugs. Results Methotrexate, mifepristone, and ritodrine were the high-frequency drugs reported for liver-related ADR in pregnant women and were mainly used for termination of ectopic pregnancy and treatment of hydatidiform mole. The relative risk analysis of liver-related ADR showed that in pregnant women, the use of methotrexate ( ROR =37.52, 95% confidence interval [ CI ]=31.35-44.89), progesterone ( ROR =7.33, 95% CI : 2.75-19.59), and dydrogesterone ( ROR =6.58, 95% CI : 2.20-19.69) was strongly associated with the risk of liver injury, and the association of methotrexate with the risk of liver injury in pregnant women was significantly stronger than that in non-pregnant women ( ROR =1.71, 95% CI : 1.47-4.36). Conclusion The potential risk of liver injury should be taken seriously in pregnant women using the drugs such as methotrexate and progesterone, so as to avoid serious adverse reactions.
